Yan Ge, Li Huangmin, Zhang Yiding, Xia Chenyan, Wang Mengxiao, Jia Yu, Shang Jin, Zhao Zhanzheng
Department of Nephrology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
School of Medicine, Zhengzhou University, Zhengzhou, Henan, China.
Front Oncol. 2022 Nov 23;12:1012889. doi: 10.3389/fonc.2022.1012889. eCollection 2022.
IgD multiple myeloma (MM) is a rare type of MM, accounting for about 1%-2% of all MMs. IgD MM always causes kidney damage and even leads to renal failure, which is the most common complication. This study aimed to explore the risk factors of renal damage and prognosis of IgD MM patients.
From March 2018 to November 2021, 85 patients with IgD MM diagnosed for the first time at the First Affiliated Hospital of Zhengzhou University were included in this study. We collected information on clinical features and laboratory examinations. Patients were divided into the renal impairment (RI) (47/85) and non-renal impairment (no-RI) (38/85) groups. Binary logistic regression was used to explore risk factors of renal damage. The Chi-square test was used to analyze the difference in chemotherapy effect between the two groups. We also analyzed whether early dialysis was beneficial to acute renal failure (RF) in IgD MM patients. Finally, Kaplan-Meier was used to compare the survival of the two groups.
In IgD MM, 55.3% of patients had renal damage as a complication, of which up to 59.6% presented with acute renal failure as the first manifestation. Serum β2-microglobulin (β2-MG) was an independent risk factor for renal damage in IgD MM ( = 0.002), but cytogenetic analysis suggested that it had no effect on patients' renal damage. There was also no significant difference in the effect of chemotherapy between the two groups ( = 0.255). In patients with acute renal failure, there was no significant difference between dialysis and no dialysis groups in the proportion of patients with improved renal function after treatment. The median overall survival (OS) of the RI group was significantly shorter than that of the no-RI group ( = 0.042). In the RI group, the median OS was 29 months, and in the no-RI group, the median OS was > 40 months.
Elevated serum β2-MG is an independent risk factor for renal damage. Compared with the no-RI group, patients in the RI group had poorer prognosis and shorter median OS. For patients with acute renal failure as the first manifestation, the treatment of primary disease is more meaningful than dialysis.
IgD型多发性骨髓瘤(MM)是一种罕见的MM类型,约占所有MM的1%-2%。IgD MM常导致肾脏损害,甚至引发肾衰竭,这是最常见的并发症。本研究旨在探讨IgD MM患者肾脏损害的危险因素及预后情况。
2018年3月至2021年11月,纳入郑州大学第一附属医院首次诊断的85例IgD MM患者。收集临床特征及实验室检查信息。将患者分为肾功能损害(RI)组(47/85)和无肾功能损害(no-RI)组(38/85)。采用二元逻辑回归分析肾脏损害的危险因素。采用卡方检验分析两组化疗效果的差异。还分析了早期透析对IgD MM患者急性肾衰竭(RF)是否有益。最后,采用Kaplan-Meier法比较两组的生存率。
在IgD MM中,55.3%的患者有肾脏损害这一并发症,其中高达59.6%以急性肾衰竭为首发表现。血清β2-微球蛋白(β2-MG)是IgD MM患者肾脏损害的独立危险因素(P = 0.002),但细胞遗传学分析表明其对患者肾脏损害无影响。两组化疗效果也无显著差异(P = 0.255)。在急性肾衰竭患者中,透析组与未透析组治疗后肾功能改善患者的比例无显著差异。RI组的中位总生存期(OS)显著短于no-RI组(P = 0.042)。RI组的中位OS为29个月,no-RI组的中位OS大于40个月。
血清β2-MG升高是肾脏损害的独立危险因素。与no-RI组相比,RI组患者预后较差,中位OS较短。对于以急性肾衰竭为首发表现的患者,治疗原发病比透析更有意义。